Senyint Completes RMB 500 Million Series E Funding to Advance High-Quality Development of Public Hospitals and Public Health Systems

VCBeat (WeChat: vcbeat) has learned that on July 9, SYNYI·AI announced the completion of its RMB 500 million Series E financing round. The round was led by IDG Capital, with participation from Longmen Investment and Sharewin Investment. Since its establishment in 2016, the company has secured multiple rounds of funding from prominent Chinese investment firms, including ZhenFund, Sequoia China, CEC Health Fund, GGV Capital, Xianghe Capital, Tencent, Sinopharm Capital, CICC Jiazi, and Sunshine Insurance Group.

Zhang Shaodian, Founder and CEO of SYNYI·AI, stated, “Over the next three to five years, SYNYI·AI will remain committed to its vision of being a leader in intelligent healthcare and a guardian of billions of lives. Aligning closely with China’s 14th Five-Year Plan and the Long-Range Objectives Through the Year 2035, we strive to provide comprehensive, full-lifecycle health services to the public. Meanwhile, we will further strengthen our market positioning as a leading provider of integrated smart healthcare solutions in China, increase R&D investment in holistic solutions for smart hospitals and smart health administration, and fully support the high-quality development of public hospitals and the construction of the public health system.”

Over the past five years since its establishment, SYNYI·AI has maintained a trajectory of rapid growth. To date, personnel with medical backgrounds account for 25% of the company’s workforce, and the R&D team comprises over 400 members. SYNYI·AI’s solutions have achieved widespread success across multiple domains, including smart hospitals and intelligent health administration, continuously addressing the genuine needs of healthcare clients.

SYNYI·AI Solutions Development Timeline

Against the backdrop of the accelerated digital transformation under China’s 14th Five-Year Plan, hospitals are rapidly transitioning from informatization to a new era characterized by comprehensive datafication and intelligence. The compound annual growth rate (CAGR) of the medical datafication and intelligence market stands at approximately 300%, more than ten times the growth rate of the traditional healthcare informatization industry.

In 2020, despite the impact of the pandemic, SYNYI·AI maintained rapid business growth, with revenue increasing fourfold compared to 2019. Among the top 100 hospitals listed in the Fudan University-affiliated "2019 China Hospital Rankings," over 30% have partnered with SYNYI·AI. Currently, the company serves more than 150 Grade A tertiary hospitals across China, and this client base continues to expand rapidly.

In response to digital transformation, SYNYI·AI is also actively leveraging artificial intelligence and big data to provide technological empowerment. In 2021, the Shanghai Municipal Commission of Economy and Informatization and the Shanghai Shenkang Hospital Development Center jointly launched the Municipal Hospital Medical-Enterprise Collaborative Research and Innovation Platform (HI-CLIP)—the Clinical Trial Accelerator, which has provided strong support for biomedical R&D and the conversion of patent achievements. The technical supporter behind this platform is SYNYI·AI.

As an expert in the digitalization and intelligent transformation of hospitals, SYNYI·AI’s strength lies in its thorough understanding of national policy requirements, its courage to break away from the traditional framework of Health Information Technology (HIT) systems, and its ability to drive deep innovation tailored to the actual needs of hospitals while ensuring practical implementation. Meanwhile, the company strictly complies with laws and regulations such as the Data Security Law, ensuring the compliance and security of medical data.

In 2021, the General Office of the State Council issued the “Opinions on Promoting High-Quality Development of Public Hospitals” (hereinafter referred to as the “Opinions”), which called for advancing the construction of “smart hospitals” integrating electronic medical records, smart services, and smart management, as well as promoting the standardization of hospital information systems. It is evident that building robust smart hospitals is an essential path for hospitals to achieve high-quality development.

At the 2021 CHINC Conference, SYNYI·AI’s SYNERGY Smart Hospital Solution was unveiled for the first time. The solution is built on the “12306” framework,1 Goal, 2 Technologies, 3 Connotations, All-around Closed Loop (0), 6 Major Scenarios.The new development model of “Senyi Hao” addresses issues such as inadequate data governance, low levels of intelligence, unclear value orientation, lack of closed-loop resolution mechanisms, and incomplete business scenarios. Meanwhile, SYNERGY supports hospitals in achieving certifications for Smart Hospital, Interconnectivity, and Electronic Medical Record (EMR) grading, thereby facilitating their pursuit of high-quality development.

The “12306” Integrated Construction Solution Centered on Smart Hospitals and Powered by “Senyi Hao”

In the high-quality development of public hospitals, data serves as the core of information technology infrastructure. Data quality is paramount to the research and application of key data models and artificial intelligence. Under Senyi Intelligence’s “12306” framework,Data Integration and Governance, Smart Research, Smart Clinical Care, Smart ManagementOnce these solutions achieve comprehensive integration, they will better empower the high-quality development of public hospitals.

In the future, SYNYI·AI will closely align with the 14th Five-Year Plan and the Outline of Long-Range Objectives Through the Year 2035. While supporting the high-quality development of public hospitals and the construction of the public health system, the company, guided by its vision to be a leader in intelligent healthcare and a guardian of billions of lives, strives to provide comprehensive, full-lifecycle health services for the people.

IDG Capital Managing Director Zhang Sai“He stated: ‘The healthcare services industry is a time-honored sector that has long relied on experience, and its digital transformation is only just beginning. As a leading enterprise in the industry, SYNYI·AI started with research tools and has gradually expanded its business boundaries to encompass numerous data application scenarios. IDG Capital is honored to partner with the highly dynamic team led by Zhang Shaodian as we jointly explore the rapidly growing and promising market for healthcare digitalization.’”

Fan Zhe, Partner at Longmen Investmentstated: “Dr. Zhang Shaodian is an outstanding representative of the new generation of young entrepreneurs. SYNYI·AI’s core AI products are positioned at critical junctures within hospital clinical scenarios. We look forward to SYNYI·AI’s continued deepening of collaboration with key hospital departments, thereby providing greater possibilities for the development of China’s smart healthcare infrastructure.”

Shen Qin, Managing Partner at Sharewin Investmentstating: “Amidst the wave of new infrastructure development in hospitals, SYNYI·AI has developed a series of smart hospital solutions, including a big data research platform and VTE management systems, based on artificial intelligence technology and premised on meeting clinical needs. After five years of technological advancement and case accumulation, SYNYI·AI has established itself as an industry leader, with a promising future ahead!”

IDG Capital pioneered venture capital operations in China in 1993. To date, it has invested in over 1,000 outstanding companies worldwide, with more than 300 successful exits. IDG Capital focuses on leading enterprises in sectors such as Technology, Media, and Telecom (TMT), new consumption and services, culture and entertainment, healthcare, advanced manufacturing, and clean energy. Its investment scope covers all stages, including start-up, growth, maturity, and mergers and acquisitions. In the healthcare sector, its portfolio includes renowned companies such as MGI Tech, Suzhou Cailike, Ping An Good Doctor, EdithGene, Highcon Bio, Biobase, Zhenge Biotechnology, Shengsi Biotech, MicroTech Medical, Keya Medical, and AccutarBio.

The cornerstone investors of Zhongguancun Longmen Investment include the National Social Security Fund and the Beijing Municipal Government, among others. Longmen Investment regards facilitating the “critical leap” for outstanding enterprises as its mission, striving to become the preferred cooperation platform for industry-leading companies and promoting the development of China’s technological innovation through equity investments in technology enterprises.

Since 2011, Sharewin Medical’s investment team has focused its strategic layout in the broader healthcare industry—centered on IVD and biopharmaceuticals, medical devices and consumables, and smart healthcare—by adhering to the strategies of “specialization” and “industrial partnership.” In the smart healthcare sector, Sharewin has invested in a cohort of technological leaders in niche markets, fostering product and channel synergies within the Sharewin Medical ecosystem.